November 28, 2025 — Leads & Copy — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) has announced that CTV News’ W5 investigative program aired Part 2 of a three-part series about the company and its allegations of stock market manipulation.
Award-winning CTV News journalist Jon Woodward highlights the second part of the series in an article entitled, “‘Something was wrong’: Inside a Canadian biotech firm’s fight to prove ‘stock spoofing’”. The series explores “stock spoofing,” an illegal market manipulation tactic in Canada and the United States, and the basis of a USD $700 million lawsuit by Quantum Biopharma against two of Canada’s largest banks, CIBC and RBC.
The second part of the W5 investigative series can be viewed on CTV News at: W5: Quantum BioPharma seeks $700M in stock spoofing lawsuit. Part 1 can be viewed at: W5: MS research derailed by stock market spoofing: lawsuit.
Quantum BioPharma CEO Zeeshan Saeed thanked W5 for its investigation into stock spoofing and its effects on retail investors. He stated that their goal has been to bring Lucid-MS, a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis), giving back mobility and control to the body unlike any drug today for millions of people around the world who live with this debilitating disease. By shining a light on our experience with alleged stock market manipulation, they hope to prevent other companies, their shareholders, and their beneficiaries from experiencing what we have been through.
Quantum BioPharma Co-Executive Chair Anthony Durkacz added that the USD $700 million lawsuit against CIBC and RBC alleges that Canadian exchange trading data clearly show stock spoofing on a massive scale intended to manipulate Quantum BioPharma’s stock price. He stated that banks and brokers have the responsibility to act as gatekeepers and ensure their clients and traders do not breach trading rules and regulations or engage in illegal activity such as stock spoofing. The company alleges that at least 16 million illegal and fictitious orders came from Canadian bank platforms.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, can be contacted at Zsaeed@quantumbiopharma.com or by telephone at (833) 571-1811.
Source: Quantum BioPharma
